Removal Notice to “An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C”: Med Clin N Am 98 (2014) 17–38 (REMOVED: An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C (2014) 98(1) (17), (S0025712513001594), (10.1016/j.mcna.2013.10.011));An overview of emerging therapies for the treatment of chronic hepatitis C

Medical Clinics of North America

Volumn 98, Issue 1, 2014, Pages 17-38

  Ilyas, Jawad A ^a   Vierling, John M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Boceprevir; Chronic hepatitis C; Cyclophilin inhibitors; Direct acting antivirals; Polymerase inhibitors; Protease inhibitors; Telaprevir; Therapeutic vaccines

Indexed keywords

ABT 333; ACH 1625; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BALAPIRAVIR; BI 207127; BILB 1941; BMS 824393; BMS 986094; BOCEPREVIR; CILUPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; GI 5005; IDX 184; IDX 375; LANTHANUM; LEDIPASVIR; MERICITABINE; MK 5172; MONTIRELIN; NARLAPREVIR; NIVOCASAN; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHX 1766; PLACEBO; PPI 461; PSI 938; RIBAVIRIN; RITONAVIR; SCY 635; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VALOPICITABINE; VANIPREVIR; VCH 222; VCH 759; VIRUS RNA;

ADD ON THERAPY; ANEMIA; ANTIVIRAL THERAPY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HEMORRHOID; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE; LOADING DRUG DOSE; MONOTHERAPY; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REVIEW; TASTE DISORDER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE; VOMITING;

EID: 84888020792     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.01.001     Document Type: Erratum

References (51)

1. Kim W.R. The burden of hepatitis C in the United States. Hepatology 2002, 36:S30-S34.
2. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
3. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEngl J Med 2002, 347:975-982.
4. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
5. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. NEngl J Med 1998, 339:1485-1492.
6. Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. JHepatol 2004, 40:993-999.
7. Bartenschlager R., Frese M., Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004, 63:71-180.
8. Lamarre D., Anderson P.C., Bailey M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
9. Lange C.M., Sarrazin C., Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment Pharmacol Ther 2010, 32:14-28.
10. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. NEngl J Med 2009, 360:1827-1838.
11. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. NEngl J Med 2009, 360:1839-1850.
12. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. NEngl J Med 2010, 362:1292-1303.
13. Marcellin P., Forns X., Goeser T., et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011, 140(2):459-468.
14. Jacobson I.M., McHutchison J.G., Dusheiko G.M., et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naive patients: final results of phase 3 ADVANCE study. Hepatology 2010, 52:427A.
15. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment naive genotype 1 HCV patients who achieved an extended viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010, 52:LB-2.
16. Vertex's and Tibotec [press release]; Cambridge (MA): Vertex Pharmaceuticals; September 7, 2010.
17. Zeuzem S., Sulkowski M.S., Zoulim F., et al. Long term follow up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 2010, 52:436A.
18. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
19. Poordad F., McCone J., Bacon B., et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis C. NEngl J Med 2011, 364:1195-1206.
20. Bacon B., Gordon S., Lawitz E., et al. Boceprevir for treatment-resistant chronic HCV genotype 1 infection. NEngl J Med 2011, 364:1207-1217.
21. Vierling J., Lawitz E., Poordad F., et al. Four-week therapy with peginterferon alfa-2b/ribavirin effectively predicts sustained virologic response in treatment-naive and treatment-experienced patients with HCV-1 treated with boceprevir plus peginterferon alfa-2b/ribavirin. JHepatol 2011, 54:S197.
22. Zeuzem S., Vierling J., Estaban R., et al. Predictors of sustained virologic response among treatment-experienced patients with hepatitis C virus genotype 1 when re-treated with boceprevir plus peginterferon alfa-2b/ribavirin. JHepatol 2011, 54:S199.
23. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
24. Lin C., Gates C.A., Rao B.G., et al. Invitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. JBiol Chem 2005, 280:36784-36791.
25. Lin K., Kwong A.D., Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and α interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004, 48:4784-4792.
26. Lin K., Perni R.B., Kwong A.D., et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006, 50:1813-1822.
27. Kieffer T.L., Sarrazin C., Miller J.S., et al. Telaprevir and pegylated interferon-α-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46:631-639.
28. McCown M.F., Rajyaguru S., Kular S., et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009, 53:2129-2132.
29. Tong X., Chase R., Skelton A., et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006, 70:28-38.
30. Vierling J.M., Ralston R., Lawitz E., et al. Long term outcomes following combination treatment with boceprevir plus pegintron/ribavirin (P/R) in patients with chronic hepatitis C genotype 1 (CHC-G1). JHepatol 2010, 52:S470.
31. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 patients without treatment options. N Engl J Med 2013 May 16, 368(20):1867-1877.
32. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013 May 16, 368(20):1878-1887.
33. Beaulieu P.L. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007, 8:614-634.
34. Pockros P.J., Nelson D., Godofsky E., et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008, 48:385-397.
35. Kieffer T.L., Kwong A.D., Picchio G.R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). JAntimicrob Chemother 2010, 65:202-212.
36. Shi S.T., Herlihy K.J., Graham J.P., et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009, 53:2544-2552.
37. Shih I.H., Vliegen I., Peng B., et al. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2011 Sep, 55(9):4196-4203.
38. Pol S., Everson G., Ghalib S., et al. Once daily NS5A Inhibitor(BMS-790052) plus peginterferon-α 2a and ribavirin produces high rates of extended rapid virologic response in treatment naive HCV genotype 1 subjects: phase 2a trial. Hepatology 2010, 52:S462.
39. Gane E.J., Roberts S.K., Stedman C.A., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376:1467-1475.
40. A study on the combination of RO5024048 and ritonavir-boosted danoprevir with and without Copegus (Ribavirin) in interferon-naïve patients with chronic hepatitis C genotype 1 (INFORM-SVR). 2011. Available at: Accessed February 25, 2011. http://clinicaltrials.gov/ct2/show/NCT01278134.
41. Muir A.J., Shiffman M.L., Zaman A., et al. Phase 1b study of pegylated interferon λ 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52:822-832.
42. Flisiak R., Feinman S.V., Jablkowski M., et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009, 49:1460-1468.
43. Nelson D., Ghalib R., Sulkowski M., et al. Efficacy and safety of the cyclophilin inhibitor DEBIO 025 in combination with pegylated interferon α 2a and ribavirin in previously null-responder genotype 1 HCV patients. JHepatol 2010, 50(Suppl 1):S40.
44. Hopkins S., Heuman D., Gavis E., et al. Safety, plasma pharmacokinetics and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. JHepatol 2009, 50(Suppl 1):S36.
45. Manns M., Lawitz E., Hoepelman A. Short term safety, tolerability, pharmacokinetics and preliminary activity of GS-9450, a selective caspase inhibitor in patients with chronic HCV infection. JHepatol 2010, 52(Suppl 1):S114-S115.
46. Available at:, Accessed February 25, 2011. http://www.globeimmune.com/products/gi-5005/.
47. Jacobson S., McHutchison J., Boyer T. GI-5005 therapeutic vaccine plus PEG-IFN/Ribavirin significantly improves virologic response and ALT normalization at end of treatment and improves SVR24 compared to PEG-IFN/Ribavirin in genotype 1 chronic HCV patients. JHepatol 2010, 52(Suppl 1):S465-S466.
48. Ge D., Fellay J., Thompson A., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
49. Pockros P., Jacobson I., Boyer T., et al. GI-5005 therapeutic vaccine plus Peg-IFN/ribavirin improves sustained virological response versus Peg-IFN/Ribavirin in prior non-responders with genotype 1 chronic HCV infection. Hepatology 2011, 52:404A.
50. Vierling J., McHutchison J., Jacobson I., et al. GI-5005 therapeutic vaccine improves deficit in cellular immunity in IL28B Genotype T/T, treatment naive patients with Chronic hepatitis C genotype 1 when added to standard of care(SOC) PEG-IFN-α-2a/Ribavirin. Hepatology 2011, 52:1258A.
51. Available at:, Accessed February 25, 2011. http://www.conatuspharma.com/products/cts-1027-for-liver-disease.htm.